Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials

Fig. 2

Percent change from baseline in CDAI in patients with early RA from a PREMIER and b OPTIMA, or established RA from c DE019 and d ARMADA at week 24/26. P value for difference between response rates for patients treated with ADA+MTX and PBO+MTX. ADA, adalimumab; CDAI, Clinical Disease Activity index; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us